undamentalytics Newsletter

Mimedx Group, Inc. insider trading

Every open-market purchase and sale by Mimedx Group, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Mimedx Group, Inc.’s insiders pay?

From January 5, 2010 to November 10, 2025, 24 insiders reported 18 open-market purchases and 65 sales not made under a pre-set plan in Mimedx Group, Inc. Twelve months after each purchase was reported, the shares were +21.9% against the S&P 500 on average (median +10.1%), over 11 purchases with a full year of prices; 64% beat the index. After sales, the shares moved −23.4% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 14, 2013 into $12,531 by November 2, 2026, +1.7% a year. It held shares 37% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $29,185 (+8.3% a year), and held throughout $57,539 (+13.9%).

$0$20.0k$40.0k$60.0k 2013201520172019202120232025 $57.5k$29.2k$12.5k
Copying Mimedx Group, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Mimedx Group, Inc.'s insiders from May 14, 2013, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 37% of the time.
Mimedx Group, Inc.: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Stein Robert Benjamin President, Regenerative Med. 0 — — 12 −13.4% (4) May 17, 2023
Hulse William Frank IV General Counsel and CAO 0 — — 10 −29.6% (5) March 14, 2025
Petit Parker H Chairman & CEO 8 +73.6% (5) 100% 1 −11.5% (1) May 23, 2016
Carlson Peter M Chief Financial Officer 0 — — 8 −2.9% (2) May 12, 2023
Gorlin Steve Director 0 — — 6 −26.7% (2) May 30, 2013
Maersk-Moller Kimberly Chief Commercial Officer 0 — — 4 −64.6% (3) November 10, 2025
Phelan William Lawrence Chief Accounting Officer 0 — — 4 −0.4% (1) May 3, 2023
Graves Mark SVP & Chief Compliance Officer 0 — — 3 −16.1% (1) May 10, 2022
Taylor William Charles President and COO 0 — — 3 −1.6% (2) August 30, 2013
Turner Scott M SVP, Operations & Procurement 0 — — 3 −9.1% (1) May 4, 2022
Whitlow Ricci S Chief Operating Officer 0 — — 3 −31.3% (3) February 18, 2025
Wright Timothy R Chief Executive Officer 0 — — 3 −9.1% (1) June 13, 2022
Capper Joseph H Chief Executive Officer 2 −49.0% (2) 0% 0 — May 5, 2025
Kashyap Rohit President, WC & Surgical 0 — — 2 — August 11, 2022
Koob Charles E Director 1 — — 1 −32.7% (1) March 15, 2017
Bleser Joseph G Director 1 −36.7% (1) 0% 0 — May 13, 2013
Doug Rice Chief Financial Officer 1 −14.3% (1) 0% 0 — November 22, 2023
Eichler Kurt M Director 1 — — 0 — January 4, 2011
Evans Charles Robert Director 1 +8.4% (1) 100% 0 — November 16, 2015
Haden Alexandra O General Counsel & Secretary 1 +13.3% (1) 100% 0 — October 30, 2015
Mccaw Roberta L General Counsel and Secretary 1 — — 0 — August 8, 2012
Okumus Opportunistic Value Fund Ltd. 10% owner 0 — — 1 — January 24, 2019
Papasan Larry W Director 0 — — 1 −25.4% (1) May 29, 2015
Yeston Neil Director 1 — — 0 — December 18, 2012

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Mimedx Group, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Mimedx Group, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −13.3% against the index. After 2 selling crowds, −22.5%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
March 31, 20253 selling−28.9%−27.9%−66.5%
February 28, 20223 selling−19.6%−17.1%−9.1%
November 30, 20153 buying+3.5%−13.3%+0.7%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Mimedx Group, Inc. · Funds · Politicians